Xenetic Biosciences to Hold Business Update Conference Call January 20th
LEXINGTON, Mass.-- Xenetic Biosciences, Inc. (OTCBB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, will hold a conference call on Tuesday, January 20, at 12:00 UK time, 7:00 a.m. ET. M. Scott Maguire, chief executive officer, and Colin Hill, chief financial officer and board member, will provide a business update and answer questions.
To access the conference call, U.K.-based participants should call 0800 368 0649, and participants in all other locations should call +44 20 3059 8125. The participant password will be: Sciences. A telephone replay will be available for seven days following the call’s conclusion. Replay dial-in numbers are as follows: United Kingdom 0121 260 4861; United States 866-268-1947; and all other locations + 44 121 260 4861. Please provide conference ID 3245500# when accessing the replay. In addition, the call will be webcast and available at the Investor Relations section of www.xeneticbio.com in the “Events and Presentations” tab.
About Xenetic Biosciences
Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for creating next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs and OncoHist® for the development of novel oncology drugs focused on orphan indications. Xenetic's lead product candidates include ErepoXen®, an improved, polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease and OncoHist®, a recombinant human histone H1.3 molecule which Xenetic is developing for the treatment of refractory Acute Myeloid Leukemia (AML). Xenetic is developing a novel series of polysialylated blood coagulation factors through its license agreement with major shareholder Baxter International Inc. potentially worth as much as $100 million plus royalty payments. Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications. For more information, please visit the company's website at www.xeneticbio.com.
Xenetic Biosciences Inc.
M. Scott Maguire, Chief Executive Officer
Kim Sutton Golodetz, 212-838-3777
Mike Wort, +44 (0)20 7933 8780
Source: Xenetic Biosciences, Inc.
Released January 16, 2015